邢曙光 馬珺珂 任慧 孫軍
【摘要】 目的:探討中性粒細胞/淋巴細胞(NLR)在2型糖尿?。═2DM)合并非酒精性脂肪肝(NAFLD)患者中的臨床價值。方法:選取2018年9月-2020年8月于錦州市中心醫(yī)院就診的T2DM患者110例。根據(jù)超聲檢查有無脂肪肝將患者分為T2DM合并NAFLD組(T2DM+NAFLD組)56例和T2DM不合并NAFLD組(T2DM組)54例。比較兩組臨床資料,多因素logistic回歸分析T2DM合并NAFLD的影響因素,采用ROC曲線分析NLR在T2DM合并NAFLD患者中的臨床價值。結(jié)果:T2DM+NAFLD組HbA1c、FBG、HOMA-IR、TG、TC、ALT、AST、WBC、NLR均高于T2DM組,HDL-C低于對照組,差異均有統(tǒng)計學意義(P<0.05)。logistic回歸分析結(jié)果顯示,F(xiàn)BG、TC、ALT、NLR是T2DM合并NAFLD的獨立危險因素,HDL-C為T2DM合并NAFLD的保護因素(P<0.05)。ROC曲線分析結(jié)果顯示,NLR診斷T2DM合并NAFLD的AUC為0.790,最佳診斷點為2.39,靈敏度和特異度分別為60.7%、86.8%。結(jié)論:T2DM合并NAFLD患者中NLR顯著增高,是其發(fā)病的獨立危險因素且對其具有良好預測價值。
【關(guān)鍵詞】 中性粒細胞/淋巴細胞 2型糖尿病 非酒精性脂肪肝
[Abstract] Objective: To investigate the clinical value of neutrophil / lymphocyte (NLR) in patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Method: A total of 110 T2DM patients treated in Jinzhou Central Hospital from September 2018 to August 2020 were selected. According to the presence or absence of fatty liver by ultrasonography, the patients were divided into 56 cases in T2DM with NAFLD group (T2DM + NAFLD group) and 54 cases in T2DM without NAFLD group (T2DM group). The clinical data of the two groups were compared, the influencing factors of T2DM combined with NAFLD were analyzed by multivariate logistic regression, and the clinical value of NLR in patients with T2DM combined with NAFLD was analyzed by ROC curve. Result: HbA1c, FBG, HOMA-IR, TG, TC, ALT, AST, WBC and NLR in T2DM+NAFLD group were higher than those in T2DM group, and HDL-C was lower than that in control group, the differences were statistically significant (P<0.05). logistic regression analysis showed that FBG, TC, ALT and NLR were independent risk factors for T2DM combined with NAFLD, and HDL-C was a protective factor for T2DM combined with NAFLD (P<0.05). ROC curve analysis results showed that the AUC of NLR for diagnosing T2DM combined with NAFLD was 0.790, the optimal diagnostic point was 2.39, and the sensitivity and specificity were 60.7% and 86.8%, respectively. Conclusion: NLR is significantly increased in T2DM patients with NAFLD, which is an independent risk factor and has good predictive value.
[Key words] Neutrophil/lymphocyte ratio Type 2 diabetes mellitus Nonalcoholic fatty liver disease
First-author’s address: Graduate School of Jinzhou Medical University, Jinzhou 121000, China
doi:10.3969/j.issn.1674-4985.2021.25.036
非酒精性脂肪肝(nonalcoholic fatty liver disease, NAFLD)是一種代謝紊亂的多系統(tǒng)疾病,與高血糖、高血脂、肥胖等多種代謝性疾病密切相關(guān),且相互影響[1-2]。與非糖尿病NAFLD患者相比,伴有2型糖尿病(type 2 diabetes mellitus, T2DM)的NAFLD患者病情更加嚴重,且促進向非酒精性脂肪性肝炎(nonalcoholic steatohepatitis, NASH)進展,增加肝臟纖維化和肝細胞癌(hepatocellular carcinoma, HCC)的患病風險[3]。因此較早發(fā)現(xiàn)、較早干預可以延緩患者病情的進展、減少相關(guān)疾病的發(fā)生率有重要意義。目前肝活檢仍然是NAFLD診斷的金標準,但由于肝臟活檢為有創(chuàng)性檢查,可導致某些并發(fā)癥,且存在抽樣誤差,因此臨床難以廣泛展開,在早期診斷NAFLD方面還缺少有效的、高特異性的方法。近年來,中性粒細胞/淋巴細胞(neutrophil/lymphocyte ratio, NLR)作為一種炎癥指標受到廣泛關(guān)注,該指標具有廉價、容易獲得等優(yōu)點,常用于心血管疾病和腫瘤的評估[4-6],但近期研究表明,NLR與糖尿病的并發(fā)癥相關(guān)[7],NLR亦對肝病具有預測價值,Chen等[8]研究顯示,NLR對HCC有預測價值;梁利民等[9]研究顯示,NLR對乙型肝炎后肝硬化預后亦有預測價值,但關(guān)于NLR與T2DM合并NAFLD的相關(guān)性研究較少。本文擬探討NLR與T2DM合并NAFLD的相關(guān)性,從而了解NLR對T2DM合并NAFLD的預測價值?,F(xiàn)報道如下。
1 資料與方法
1.1 一般資料 選取2018年9月-2020年8月于錦州市中心醫(yī)院就診的T2DM患者110例。(1)納入標準:T2DM患者,年齡>18歲;NAFLD的診斷符合《非酒精性脂肪性肝病防治指南2018年更新版》[10];糖尿病的診斷符合中華醫(yī)學會糖尿病分會《2017年的中國糖尿病防治指南》[11]。(2)排除標準:其他原因?qū)е碌闹靖?,包括藥物性肝損害、自身免疫性肝炎、酒精性肝病、病毒性肝炎、全胃腸外營養(yǎng)等可能導致肝損害的疾病;全身嚴重疾病,包括腫瘤、腦卒中、心肌梗死以及終末期腎病等;妊娠期或哺乳期女性;臨床數(shù)據(jù)不全。根據(jù)超聲檢查有無脂肪肝將患者分為T2DM合并NAFLD組(T2DM+NAFLD組)56例和T2DM不合并NAFLD組(T2DM組)54例。研究對象及家屬均簽署知情同意書,研究獲倫理委員會批準。
1.2 方法
1.2.1 一般資料采集 研究對象均清晨脫鞋、免冠,測量身高、體重(精確到0.1 kg)、腰圍(WC)、臀圍(HC),并計算身體質(zhì)量指數(shù)(BMI)=體重(kg)/身高2(m2)、腰臀比(WHR)=腰圍(cm)/臀圍(cm);休息0.5 h后平臥位測量右上肢血壓三次,取平均值。記錄患者既往是否有高血壓、吸煙史及飲酒史等。
1.2.2 實驗室檢查 研究對象均需隔夜空腹至少8 h,次日清晨抽取靜脈血檢測空腹血糖(FPG)、餐后2小時血糖(2 h PBG)、甘油三酯(TG)、總膽固醇(TC)、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C)、谷丙轉(zhuǎn)氨酶(ALT)、谷草轉(zhuǎn)氨酶(AST)、血尿酸(UA)、白細胞計數(shù)(WBC)、NLR,均采用AU5800系列全自動生化分析儀(美國貝克曼庫爾特有限公司)檢測;并檢測空腹胰島素(FINS)和糖化血紅蛋白(HbA1c);穩(wěn)態(tài)模型評估胰島素抵抗指數(shù)(HOMA-IR)=FPG(mmol/L)×FINS(mU/L)/22.5;中性粒細胞、淋巴細胞計數(shù)及分類檢測采用貝克曼庫爾特LH755全自動血液分析儀分析。
1.2.3 影像學檢查 研究對象空腹8 h后于晨起行肝臟彩色多普勒超聲檢查,儀器采用PHILIPS 5500型和7500超聲儀,設(shè)定融合為頻率2~4 MHz。NAFLD的影像學診斷標準符合《非酒精性脂肪性肝病防治指南2018年更新版》[10],即符合以下3項當中的2項,肝臟超聲顯示:近場回聲彌漫性增強,遠場回聲減弱;肝臟內(nèi)部實質(zhì)回聲致密,腎臟實質(zhì)低于肝臟實質(zhì)回聲;肝內(nèi)血管和膽道的結(jié)構(gòu)顯示不清。
1.3 觀察指標 比較三組臨床資料,包括收縮壓(SBP)、舒張壓(DBP)、體質(zhì)量指數(shù)(BMI)、WHR、HbA1c、FBG、2 h PBG、HOMA胰島素指數(shù)(HOMA-IR)、TG、TC、AST、ALT、LDL-C、HDL-C、UA、WBC。分析NLR與ALT、AST的相關(guān)性。多因素logistic回歸分析T2DM合并NAFLD的影響因素。分析NLR對T2DM合并NAFLD患者的評估價值。
1.4 統(tǒng)計學處理 采用SPSS 23.0軟件對所得數(shù)據(jù)進行統(tǒng)計分析,符合正態(tài)分布的計量資料用(x±s)表示,比較采用t檢驗;計數(shù)資料以率(%)表示,比較采用字2檢驗。影響因素采用二元多因素logistic回歸分析。通過受試者工作特征曲線(receiver operating characteristic,ROC)分析計算NLR在T2DM合并NAFLD患者中的臨床價值。以P<0.05為差異有統(tǒng)計學意義。
2 結(jié)果
2.1 兩組臨床資料比較 T2DM+NAFLD組HbA1c、FBG、HOMA-IR、TG、TC、ALT、AST、WBC、NLR均高于T2DM組,HDL-C低于對照組,差異均有統(tǒng)計學意義(P<0.05)。兩組性別、年齡、SBP、DBP、BMI、WHR、2 h PBG、LDL-C、UA比較,差異均無統(tǒng)計學意義(P>0.05)。見表1。
2.2 T2DM合并NAFLD的多因素logistic回歸分析 以是否合并NAFLD為因變量,以組間比較具有統(tǒng)計學意義的指標為自變量,進行l(wèi)ogistic回歸分析,結(jié)果顯示FBG、TC、ALT、NLR是T2DM合并NAFLD的獨立危險因素,HDL-C為T2DM合并NAFLD的保護因素(P<0.05)。見表2。
2.3 NLR對T2DM合并NAFLD患者的評估價值分析 通過ROC曲線分析NLR對T2DM合并NAFLD患者的診斷價值,NLR診斷T2DM合并NAFLD的AUC為0.790,最佳診斷點為2.39,靈敏度和特異度分別為60.7%、86.8%。見圖1。
3 討論
隨著人們生活水平的提高及生活方式、飲食習慣的改變,NAFLD患病率逐年增高,全球患者高達10億[12-13]。我國患病率以每年0.594%的速度增長,預計2020年患病率將達到20.21%[14]。NAFLD是一種與代謝、應(yīng)激等因素有關(guān)的肝損傷,與胰島素抵抗(insulin resistance,IR)、遺傳等因素密切相關(guān),包括非酒精性肝脂肪變(non-alcoholic hepatic steatosis)、NASH、肝硬化和HCC。研究證實,40%~70%的T2DM患者同時伴有NAFLD,21%~45%的NAFLD患者同時合并糖尿病[15]。目前肝臟活檢仍然是診斷NALFD病變嚴重程度的金標準,但由于存在抽樣誤差、并發(fā)癥相對較多,加之病理結(jié)果的耗時長,因此在臨床應(yīng)用中的實施難度相對較大。目前臨床應(yīng)用最為廣泛的診斷工具是B型超聲,但其對輕度脂肪肝靈敏度低,特異性也不高。研究顯示,NAFLD進展為NASH及肝硬化過程中,炎癥狀態(tài)發(fā)揮重要作用[10,16-19],多個炎性因子已經(jīng)被證實可作為NASH的生物指標,本研究結(jié)果顯示,T2DM+NAFLD組HbA1c、FBG、HOMA-IR、TG、TC、ALT、AST、WBC、NLR均高于T2DM組,HDL-C低于對照組,差異均有統(tǒng)計學意義(P<0.05),表明NLR升高與NALFD相關(guān)。NAFLD與代謝綜合征(metabolic syndrome,Mets)、T2DM等密切相關(guān),本研究結(jié)果顯示FBG、TC、ALT、NLR是T2DM合并NAFLD的獨立危險因素,HDL-C為T2DM合并NAFLD的保護因素(P<0.05),驗證了徐建華等[20]研究結(jié)果,脂質(zhì)代謝紊亂、高血糖是糖尿病合并非酒精性脂肪肝的獨立危險因素。
基于以上的研究,筆者運用ROC曲線進一步分析NLR對T2DM合并NALFD的預測價值,ROC曲線結(jié)果顯示,NLR在該患者中風險評估中的曲線下面積為0.790,最佳診斷點為2.39,靈敏度及特異度分別為60.7%、86.8%,說明NLR在該類患者的臨床應(yīng)用中有一定的預測價值,其特異度較高,靈敏度一般,有可能與本研究樣本量較少有關(guān),可對其進行進一步研究。
綜上所述,NLR是T2DM合并NAFLD患者的獨立危險因素,可作為T2DM合并NALFD的預測指標,提高T2DM合并NALFD患者的診斷率,利于有效分配醫(yī)療資源。
參考文獻
[1] Jones T L,Neville D M,Chauhan A J.Diagnosis and treatment of severe asthma: a phenotype-based approach[J].Clinical Medicine,2018,18(Suppl 2):s36-s40.
[2] Rhee E J.Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective[J].Endocrinol Metab (Seoul),2019,34(3):226-233.
[3] Jason S,Jay B,Byron H,et al.Clinical Course of Non-Alcoholic Fatty Liver Disease: An Assessment of Severity, Progression, and Outcomes[J].Clin Epidemiol,2017,9:679-688.
[4] Lorenzo C,Hanley A J,Haffner S M.Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study[J].Diabetologia,2014,57(1):83-92.
[5] Chang Y,Ryu S,Sung K C,et al.Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: Evidence from the Kangbuk Samsung Health Study[J].Gut,2019,68(9):1667-1675.
[6] Qiao S,Gao W,Guo S.Neutrophil-Lymphocyte Ratio (NLR) for Predicting Clinical Outcomes in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus: A Propensity Score Matching Analysis[J].Therapeutics and Clinical Risk Management,2020,16:437-443.
[7] Defuria J,Belkina A C,Jagannathan-Bogdan M,et al.B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile[J].PNAS,2013,110(13):5133-5138.
[8] Chen L,Zhang Q,Chang W,et al.Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma[J].Eur J Cancer,2012,48(13):1977-1987.
[9]梁利民,徐鶴翔,鄭吉順,等.中性粒細胞與淋巴細胞比值對失代償期肝硬化患者預后的評估價值[J].臨床肝膽病雜志,2019,35(4):790-795.
[10]中華醫(yī)學會肝病學分會脂肪肝和酒精性肝病學組,中國醫(yī)師協(xié)會脂肪性肝病專家委員會.非酒精性脂肪性肝病防治指南(2018更新版)[J].實用肝臟病雜志,2018,21(2):177-186.
[11]中華醫(yī)學會糖尿病學分會.中國2型糖尿病防治指南(2017年版)[J].中華糖尿病雜志,2018,10(1):4-67.
[12] Sayiner M,Koenig A,Henry L,et al.Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World[J].Clin Liver Dis,2016,20(2):205-214.
[13] Da I W,Ling Y,Liu A,et al.Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis[J/OL].Medicine (Baltimore),2017,96(39):e8179.
[14] Zhu J Z,Zhou Q Y,Wang Y M,et al.Prevalence of fatty liver disease and the economy in China: A systematic review[J].World J Gastroenterol,2015,21(18):5695-5706.
[15]陳思思,梁曉鑫.2型糖尿病患者血尿酸與非酒精性脂肪肝的相關(guān)性研究[J].醫(yī)藥前沿,2020,10(1):108-110.
[16] Kekilli1 M,Tanoglu A,Sakin Y S,et al.Is the neutrophil to lymphocyte ratio associated with liver fibrosis in patients with chronic hepatitis B?[J].World Journal of Gastroenterology,2015,21(18):5575-5581.
[17] Leithead J A,Rajoriya N,Gunson B K,et al.Neutrophil-to-lymphocyte ratio predicts mortality in patients listed for liver transplantation[J].Liver International,2015,35(2):502-509.
[18] Clària J,Stauber R E,Coenraad M J,et al.Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J].Hepatology,2016,64(4):1249-1264.
[19] Lin L,F(xiàn)ang Y,Wang Y,et al.Prognostic nomogram incorporating neutrophil-to-lymphocyte ratio for early mortality in decompensated liver cirrhosis[J].Int Immunopharmacol,2018,56:58-64.
[20]徐建華,石群,顧紅霞,等.2型糖尿病與非酒精性脂肪肝相關(guān)性研究[J].中華全科醫(yī)學,2014,12(7):1082-1083.
(收稿日期:2020-11-16) (本文編輯:姬思雨)